← Oncology Approval Tracker

FDA DECISION ·

Bosulif

bosutinib · Pfizer

FDA approvalNew or expanded indicationChronic myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For children aged one year or older with chronic-phase Philadelphia chromosome-positive CML who are newly diagnosed or resistant or intolerant to earlier treatment.

LAMPGEN ANALYSIS

Why it matters

The expanded indication gave younger patients an additional BCR::ABL1-targeted option.

What research teams should watch

Capture phase, prior TKI tolerance and body-size data for pediatric dosing. FDA also approved lower-strength capsules.

PRIMARY RECORDS

Sources